Cytoskeleton

BeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin’s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere Models

Retrieved on: 
Tuesday, October 31, 2023
Microtubule, GBM, AACR, Therapy, Cytoskeleton, Conference, Research, Cell, Glioblastoma, University of Toledo College of Medicine and Life Sciences, Disease, Neoplasm, Drug discovery, Recurrence, University, Patient, Medical imaging

Professor Eisenmann’s research interests include glioblastoma invasion programs and developing small molecule therapeutics that target cytoskeleton networks.

Key Points: 
  • Professor Eisenmann’s research interests include glioblastoma invasion programs and developing small molecule therapeutics that target cytoskeleton networks.
  • She has built a comprehensive glioblastoma patient cell line repository of more than 6 dozen samples of primary and therapy-resistant recurrent tumors.
  • The presentation demonstrated the monotherapy activity of plinabulin at 10-30 nM at killing 3D neurospheres from five glioblastoma multiforme (GBM) patient-derived primary cell lines and therapy-resistant cell lines.
  • Plinabulin had shown single agent activity in transgenic GBM animal model with survival benefit compared to placebo,” said Dr. Kathryn Eisenmann.

Live Cell Imaging Market worth $4.3 billion | MarketsandMarkets

Retrieved on: 
Tuesday, May 30, 2023
Omni, GE HealthCare, Prevalence, FRAP, Merck Group, Olympus Corporation, Genetics, Data analysis, Neuroscience, Conditional sentence, PHI, Automation, Biomedical Research, Research, Gene expression, Photobleaching, Drug discovery, Developmental biology, Cell division, Growth, Wireless power transfer, BD, Cell biology, Corning Inc., Cancer, Cell, Government, Participation, HCS, Agilent Technologies, Eliot Porter, B cell, AX, Bruker, DSM-IV codes, Sartorius AG, Temporal, PerkinElmer, Nikon, FRET, Pharmacology, Imaging, Microscope, Pharmaceutical industry, Fine chemical, Medical imaging, Mobile phone, Retail, Cytoskeleton

The live cell imaging market in North America has experienced significant growth in recent years, showcasing a robust expansion trajectory, owing to the well-established research infrastructure, strong pharmaceutical and biotech industry, increasing government support for life science research, technological advancements in live cell imaging, and collaborative initiatives contribute to the growth of the live cell imaging market in the North America region.

Key Points: 
  • The live cell imaging market in North America has experienced significant growth in recent years, showcasing a robust expansion trajectory, owing to the well-established research infrastructure, strong pharmaceutical and biotech industry, increasing government support for life science research, technological advancements in live cell imaging, and collaborative initiatives contribute to the growth of the live cell imaging market in the North America region.
  • Live Cell Imaging Market Advantages:
    Real-Time Visualization: Live cell imaging allows researchers to observe and analyze cellular processes in real time, providing dynamic and detailed insights into cellular behavior.
  • Advancements in Imaging Technologies: The live cell imaging market benefits from continuous advancements in imaging technologies, including improved microscope systems, sensitive detectors, and fluorophores.
  • Live Cell Imaging market - Report Highlights:
    The market size is updated for the base year 2022 and forecasted from 2023 to 2028 by studying the impact of the recession on the overall live cell imaging industry.

Live Cell Imaging Market worth $4.3 billion | MarketsandMarkets

Retrieved on: 
Tuesday, May 30, 2023
Omni, GE HealthCare, Prevalence, FRAP, Merck Group, Olympus Corporation, Genetics, Data analysis, Neuroscience, Conditional sentence, PHI, Automation, Biomedical Research, Research, Gene expression, Photobleaching, Drug discovery, Developmental biology, Cell division, Growth, Wireless power transfer, BD, Cell biology, Corning Inc., Cancer, Cell, Government, Participation, HCS, Agilent Technologies, Eliot Porter, B cell, AX, Bruker, DSM-IV codes, Sartorius AG, Temporal, PerkinElmer, Nikon, FRET, Pharmacology, Imaging, Microscope, Pharmaceutical industry, Fine chemical, Medical imaging, Mobile phone, Retail, Cytoskeleton

The live cell imaging market in North America has experienced significant growth in recent years, showcasing a robust expansion trajectory, owing to the well-established research infrastructure, strong pharmaceutical and biotech industry, increasing government support for life science research, technological advancements in live cell imaging, and collaborative initiatives contribute to the growth of the live cell imaging market in the North America region.

Key Points: 
  • The live cell imaging market in North America has experienced significant growth in recent years, showcasing a robust expansion trajectory, owing to the well-established research infrastructure, strong pharmaceutical and biotech industry, increasing government support for life science research, technological advancements in live cell imaging, and collaborative initiatives contribute to the growth of the live cell imaging market in the North America region.
  • Live Cell Imaging Market Advantages:
    Real-Time Visualization: Live cell imaging allows researchers to observe and analyze cellular processes in real time, providing dynamic and detailed insights into cellular behavior.
  • Advancements in Imaging Technologies: The live cell imaging market benefits from continuous advancements in imaging technologies, including improved microscope systems, sensitive detectors, and fluorophores.
  • Live Cell Imaging market - Report Highlights:
    The market size is updated for the base year 2022 and forecasted from 2023 to 2028 by studying the impact of the recession on the overall live cell imaging industry.

Feinstein Institutes Researchers Discover a Molecule to Clear Invading Bacteria in Septic Patients

Retrieved on: 
Friday, January 6, 2023
Health, Biometrics, Other Health, General Health, Research, Science, Biotechnology, Immunosuppression, Feinstein Institute for Medical Research, Macrophage, Infection, Protein, Mouse, Bacteria, Medicine, Research, Septic, Death, Multimedia, Inflammation, Patient, Cytoskeleton, Radiation exposure, Foundation for the National Institutes of Health, Shock, Soft tissue injury, Immune system, Small intestinal bacterial overgrowth, RNA, Cell, Pharmaceutical industry, Vaccine, MD, Sepsis

(Credit Feinstein Institutes)

Key Points: 
  • (Credit Feinstein Institutes)
    The new study explores how extracellular cold-inducible RNA-binding protein (eCIRP) – an alarm molecule released during sepsis – causes immune dysfunction.
  • Specifically, eCIRP disrupts the cells within the immune system, which ingest bacteria and secrete both pro-inflammatory and antimicrobial mediators, known as macrophages.
  • “There is no single specific treatment for patients with sepsis and it remains an enigmatic disease for researchers globally,” said Dr. Wang, professor and chief scientific officer at the Feinstein Institutes.
  • “By reducing eCIRP molecules, we can lower the bacteria in septic patients and improve their outcome.

Nuevocor to Present Pre-clinical Data on its Gene Therapy Candidate for LMNA Dilated Cardiomyopathy at American Heart Association Scientific Sessions 2022

Retrieved on: 
Friday, October 28, 2022
Cell, Linker, Biotechnology, Society, Degenerative disease, LMNA, DCM, AHA, Pathology, American Heart Association, AAV, Gene, American Society of Gene and Cell Therapy, Vaccine, EU, Cytoskeleton

SINGAPORE, Oct. 28, 2022 /PRNewswire/ --Nuevocor, a pre-clinical stage cardiac gene therapy company, announced today that it will present new preclinical data on its adeno-associated virus (AAV) gene therapy for LMNA dilated cardiomyopathy at the American Heart Association (AHA) Scientific Sessions meeting on 5 7 November, 2022.

Key Points: 
  • SINGAPORE, Oct. 28, 2022 /PRNewswire/ --Nuevocor, a pre-clinical stage cardiac gene therapy company, announced today that it will present new preclinical data on its adeno-associated virus (AAV) gene therapy for LMNA dilated cardiomyopathy at the American Heart Association (AHA) Scientific Sessions meeting on 5 7 November, 2022.
  • This follows its maiden presentation at the American Society of Gene and Cell Therapy (ASGCT) meeting earlier this year.
  • Mutations in the LMNA gene, encoding lamin A/C, are thought to be the 2nd most frequent cause of familial dilated cardiomyopathy, affecting approximately 60,000 people in the US and EU alone.
  • Details of the presentation are as follows:
    For more information on the conference, please visit the AHA Scientific Sessions 2022 website.

ISPE Pharmaceutical Engineering® Article "AI's Promise for ATMPs" Honored with 2022 APEX Award

Retrieved on: 
Thursday, July 28, 2022
Manzano, Publishing, ISPE, International Society, Social media, Research, Medication, Alphabet Energy, Solution, CSO, Artificial intelligence, NORTH, Organization, Cytoskeleton, Achievement, Biotechnology, Patient, PE, APEX, Pharmaceutical engineering, Software as a service, Industry, DeepMind, Entrepreneurship, Association, Google, Technical, AI, Medical device, Pharmaceutical industry, Editorial, ATMP

NORTH BETHESDA, Md., July 28, 2022 /PRNewswire-PRWeb/ -- ISPE has been honored as the winner of a 2022 APEX Award for Publication Excellence in the Technical & Technology Writing category for the article "AI's Promise for ATMPs" published in the November-December 2021 issue of Pharmaceutical Engineering®. This is the third year in a row that Pharmaceutical Engineering® has been recognized with an APEX Award.

Key Points: 
  • ISPE has been honored as the winner of a 2022 APEX Award for Publication Excellence in the Technical & Technology Writing category for the article "AI's Promise for ATMPs" published in the November-December 2021 issue of Pharmaceutical Engineering.
  • This is the third year in a row that Pharmaceutical Engineering has been recognized with an APEX Award.
  • NORTH BETHESDA, Md., July 28, 2022 /PRNewswire-PRWeb/ -- ISPE has been honored as the winner of a 2022 APEX Award for Publication Excellence in the Technical & Technology Writing category for the article "AI's Promise for ATMPs" published in the November-December 2021 issue of Pharmaceutical Engineering.
  • This is the third year in a row that Pharmaceutical Engineering has been recognized with an APEX Award.

Veru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2022 ASCO Genitourinary Cancers Symposium

Retrieved on: 
Thursday, February 17, 2022
NASDAQ, Verus Pharmaceuticals, Collection, Patient, Form 10-Q, Flash, Capsule, Pregnancy, Man, Company, Tadalafil, Lilly, Cytoskeleton, Immunohistochemistry, Doctor of Philosophy, Prostate cancer, Forward-looking statement, Vaccine, Infection, Security (finance), CA, Efficiency, Private Securities Litigation Reform Act, Clinical trial, Safety, Breast, Neurotoxicity, MD, Breast cancer, Insurance, Zuclomifene, U.S. Securities and Exchange Commission, PSA, FDA, Microtubule, Gonadotropin-releasing hormone, Â, Johns Hopkins University, Lists of World Heritage Sites, Assistant professor, Neutropenia, AR, Finasteride, COVID-19, NCI-designated Cancer Center, Fast Track, Trial of the century, ASCO, CDK, GLOBE, Telehealth, Pharmaceutical industry, Birth control, Medical imaging

In this updated analysis of all 80 patients in the Phase 1b/2 clinical study, sabizabulin treatment demonstrated both cytotoxic and cytostatic antitumor activity.

Key Points: 
  • In this updated analysis of all 80 patients in the Phase 1b/2 clinical study, sabizabulin treatment demonstrated both cytotoxic and cytostatic antitumor activity.
  • At the time of data cut off for this presentation, 5 of the responders remain on study with the longest approaching 3 years on sabizabulin.
  • This Phase1b/2 clinical study supports the efficacy and safety assumptions for the ongoing Phase 3 VERACITY clinical study evaluating sabizabulin in metastatic castration and androgen receptor targeting agent resistant prostate cancer prior to IV chemotherapy.
  • Abstract Title: Phase 3 VERACITY clinical study of sabizabulin in men with metastatic castrate resistant prostate cancer who have progressed on an androgen receptor targeting agent.

Veru to Participate in Fireside Chat at the Jefferies London Healthcare Conference on November 16-18, 2021

Retrieved on: 
Monday, November 8, 2021
NDA, Mortality, Efficiency, Safety, Pharmacy, Fulvestrant, Private Securities Litigation Reform Act, BPH, Pregnancy, Breast, Telehealth, Health, Clinical trial, Prostate cancer, Finasteride, Security (finance), NASDAQ, EST, Insurance, Communist Party v. Subversive Activities Control Board, Trial of the century, COVID-19, Forward-looking statement, GMT, AR, Woman, Cytoskeleton, Vaccine, Company, GLOBE, Conference, U.S. Securities and Exchange Commission, Breast cancer, U.N, Collection, PDUFA, FC2, Webcast, Patient, FDA, Form 10-Q, Man, CDK, Pharmaceutical industry

MIAMI, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, today announced that the Company will participate in a fireside chat at the Jefferies London Healthcare Conference on November 16-18, 2021.

Key Points: 
  • MIAMI, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, today announced that the Company will participate in a fireside chat at the Jefferies London Healthcare Conference on November 16-18, 2021.
  • The fireside chat will be available on-demand between 8:00 am GMT (3:00 am EST) on November 18 and 5:00 pm GMT (12:00 pm EST) on November 19.
  • The webcast will be archived and accessible on the website for at least 30 days.
  • Veru Inc. is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast cancer and prostate cancer.

Kainomyx Announces New Funding to Advance Programs Focused on Malaria and Other Parasitic Diseases

ACT, Leishmaniasis, Biology, Artemisinin, Degenerative disease, Biochemistry, Goal, Parasitism, Drug development, PALO, Bill & Melinda Gates Foundation, Time, Open philanthropy (doctrine), Malaria, Cell, Stanford University, Health, Cytoskeleton, Bill, Therapy, GLOBE, Combination, Doctor of Philosophy, Biophysics, Pharmaceutical industry

Together, they share a conviction that there is a critical need for new therapeutic innovations for treating malaria, leishmaniasis, and other parasitic diseases.

Key Points: 
  • Together, they share a conviction that there is a critical need for new therapeutic innovations for treating malaria, leishmaniasis, and other parasitic diseases.
  • Kainomyx is focusing on targeting the cytoskeletal proteins of parasites to develop small molecule therapeutics targeted at malaria and other parasitic diseases.
  • In just over one year, Kainomyx has been successful in raising ~$15.5M to advance its programs on neglected tropical diseases with a primary focus on malaria.
  • In addition, Kainomyx received a grant of $1.97M from the Bill & Melinda Gates Foundation to advance Kainomyxs program in malaria therapeutics.

Veru Announces Positive Updated Data from Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress

Retrieved on: 
Monday, September 20, 2021
Mortality, Man, Telehealth, Efficiency, Private Securities Litigation Reform Act, Cytoskeleton, European Society for Medical Oncology, AR, Safety, ESMO, Calendar, Breast cancer, Diarrhea, Neutropenia, RECIST, Microtubule, Vaccine, Collection, Health, BPH, Pharmacy, Communist Party v. Subversive Activities Control Board, CEO, Fulvestrant, Form 10-Q, U.S. Securities and Exchange Commission, Finasteride, Clinical trial, Oncology, Neoplasm, NDA, Fatigue, NASDAQ, FDA, Endpoint security, Pregnancy, Nausea, Company, Woman, ORR, RPF, Neurotoxicity, PDUFA, Johns Hopkins, Gilead Sciences, Forward-looking statement, Lists of World Heritage Sites, Literature, GLOBE, Insurance, Assistant, Congress, Security (finance), Patient, Metastasis, CDK, Prostate cancer, FC2, Trial of the century, COVID-19, U.N, Pharmaceutical industry, Birth control

The oral presentation provided an updated analysis of mature data that combines approximately 80 patients enrolled in both the Phase 1b and 2 portions of the study.

Key Points: 
  • The oral presentation provided an updated analysis of mature data that combines approximately 80 patients enrolled in both the Phase 1b and 2 portions of the study.
  • As for safety, there were 54 men treated at the recommended Phase 2 dose of sabizabulin 63mg oral daily dosing in the Phase 1b/2 combined study.
  • In the Phase 1b/2 population with measurable disease at baseline per RECIST 1.1, the Overall Response Rate (ORR) was 21%.
  • Veru Inc.is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer.